Browse EX-10 agreements

Document

Exhibit 10.1

Execution Version

AMENDMENT NO. 14 TO THE CREDIT AGREEMENT

AMENDMENT NO. 14 to the Credit Agreement (as defined below), dated as of June 12, 2026 (this “Amendment”), among Cushman & Wakefield U.S. Borrower, LLC, a Delaware limited liability company (the “Borrower”), DTZ UK Guarantor Limited, a private limited company incorporated under the laws of England and Wales (“Holdings”), JPMorgan Chase Bank, N.A. (“JPMorgan Chase”), as administrative agent (in such capacity, the “Administrative Agent”), the Additional 2026-1 Term Lender (as defined below), the Converting 2025-2 Term Lenders (as defined below and, together with the Additional 2026-1 Term Lender, the “2026-1 Term Lenders”), and, solely for the purposes of Section 2.05 hereof, the Subsidiary Guarantors party hereto.

RECITALS

…

FIRST AMENDMENT TO CREDIT AGREEMENT

This FIRST AMENDMENT TO CREDIT AGREEMENT (this “First Amendment”) is dated as of June 12, 2026, and entered into by and between HAWK PARENT HOLDINGS LLC, a Delaware limited liability company (the “Borrower”), TRUIST BANK, as administrative agent (the “Administrative Agent”), and the Lenders party hereto, and is made to that certain Credit Agreement, dated as of June 1, 2026 (as amended, restated, amended and restated, supplemented or otherwise modified through the date hereof prior to the effectiveness of this First Amendment on the First Amendment Effective Date (as defined below), the “Existing Credit Agreement”; the Existing Credit Agreement as amended by this First Amendment, the “Amended Credit Agreement”), by and among REPAY HOLDINGS CORPORATION, a Delaware corporation, as Parent, the Borrower, the other Loan Parties party thereto from time to time, the Lenders and Issuing Banks party thereto from time to time and Truist Bank, as Administrative Agent and Swingline Lender. Capitalized terms used herein without definition shall have the same m

…

Document

Exhibit 10.1

Execution Version

AMENDMENT NO. 7 TO CREDIT AGREEMENT

    THIS AMENDMENT NO. 7 TO CREDIT AGREEMENT is entered into as of June 15, 2026 (this “Amendment”), by and among Talen Energy Supply, LLC, a Delaware limited liability company (the “Borrower”), the Subsidiary Guarantors party hereto, each Person identified on the signature pages hereof as a “2026-1 Additional Revolving Lender” (collectively, the “2026-1 Additional Revolving Lenders” and, each a “2026-1 Additional Revolving Lender”), each Person identified on the signature pages hereof as a “2026-1 Additional Stand-Alone L/C Issuer” (collectively, the “2026-1 Additional Stand-Alone L/C Issuers” and, each a “2026-1 Additional Stand-Alone L/C Issuer”), each other Stand-Alone L/C Issuer party hereto and Citibank, N.A., as Administrative Agent and Collateral Agent. Capitalized terms used but not defined herein shall have the meanings provided in the Amended Credit Agreement (as defined below).

RECITALS:

…

Intellectual Property License Agreement

 

This Intellectual Property License Agreement (“Agreement”), dated as of June 11, 2026 (the “Effective Date”), is by and between Project LightShift, Inc., a Florida corporation, with offices located at 4040 NE 2nd Avenue #7D, Miami, Florida 33137 (“Licensor” or “PLS”), and Quantum Cyber N.V., a public company organized under the laws of the Netherlands and listed on the Nasdaq Capital Market (NCM: QUCY), with offices located at 1501 Belvedere Road Suite 500, West Palm Beach, FL, 33406 (“Licensee” or “Quantum”) (collectively, the “Parties,” or each, individually, a “Party”).

 

WHEREAS, Licensor owns all right, title, and interest in and has the right to license to Licensee the Licensed Technology (as defined below);

 

WHEREAS, Licensee wishes to use the Licensed Technology in the Territory within the Licensed Field of Use (as defined below) and Licensor is willing to grant to Licensee a license to and under the Licensed Technology on the terms and conditions set out in this Agreement; and

…

VOTING AGREEMENT

 

This VOTING AGREEMENT (this “Agreement”) is entered into as of June 11, 2026, between Quantum Cyber N.V., a Dutch public company with limited liability (the “Company”) and Project LightShift, Inc., a Florida corporation (the “Stockholder”).

 

WHEREAS, as of the date hereof, the Stockholder is the sole record and beneficial owner of and has the sole power to vote (or to direct the voting of) such number of ordinary shares, €0.01 par value per share, held by the Stockholder on any applicable record date;

 

WHEREAS, the Stockholder is party to that that certain Intellectual Property License Agreement, dated as of June 11, 2026, by and between the Company and the Stockholder (the “IPL”), pursuant to which the Stockholder may receive additional ordinary shares of the Company (such shares, together with the shares held as of the date hereof by the Stockholder or otherwise acquired in the future by the Stockholder, collectively, the “Subject Shares”);

…

Milestone Pharmaceuticals Inc. 2019 Equity Incentive Plan, As Amended

 

MILESTONE PHARMACEUTICALS INC.

 

2019 EQUITY INCENTIVE PLAN

 

ADOPTED BY THE BOARD OF DIRECTORS: APRIL 10, 2019

APPROVED BY THE SHAREHOLDERS: APRIL 29, 2019

IPO DATE: MAY 8, 2019

AMENDED BY THE BOARD OF DIRECTORS: APRIL 19, 2022

APPROVED BY THE SHAREHOLDERS: JULY 5, 2022

AMENDED BY THE BOARD OF DIRECTORS: APRIL 30, 2025

APPROVED BY THE SHAREHOLDERS: JUNE 10, 2025

AMENDED BY THE BOARD OF DIRECTORS: MARCH 17, 2026

APPROVED BY THE SHAREHOLDERS: JUNE 10, 2026

 

1.              GENERAL.

…

TERMINATION AGREEMENT AND MUTUAL RELEASE

 

THIS TERMINATION AGREEMENT AND MUTUAL RELEASE (this “Agreement”) is made and entered into as of June 12, 2026 (the “Effective Date”), by and among Polomar Health Services, Inc., a Nevada corporation (“Polomar”), and Altanine, Inc., a Nevada corporation (“Altanine”), and, solely for purposes of Sections 4, 5 and 6 hereof, Pinata Holdings Inc., a Delaware corporation and wholly owned subsidiary of Altanine (“Pinata”). Polomar and Altanine are each referred to herein as a “Party” and collectively as the “Parties.”

 

RECITALS:

 

WHEREAS, the Parties, together with Polomar Merger Sub, Inc., a Nevada corporation and wholly owned subsidiary of Polomar (“Merger Sub”), entered into that certain Agreement and Plan of Merger dated as of July 23, 2025 (the “Original Merger Agreement”), providing for the merger of Merger Sub with and into Altanine, with Altanine surviving as a wholly owned subsidiary of Polomar (the “Contemplated Merger”);

…

Exhibit 10.01

NOTE PURCHASE AGREEMENT

THIS NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of June 9, 2026 (the “Execution Date”), is entered into by and between zeo energy corp., a Delaware corporation (the “Company”), and WHITE LION CAPITAL LLC, a Nevada limited liability company (the “Buyer”). Each capitalized term used herein shall have the meaning ascribed thereto in Section 10 below, or as otherwise defined herein.

WHEREAS, the Company and the Buyer are executing and delivering this Agreement in reliance upon an exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”); and

…

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights Agreement (this “Agreement”) is entered into effective as June 9, 2026 (the “Execution Date”), by and between Zeo Energy Corp., a Delaware corporation (the “Company”), and White Lion Capital LLC, a Nevada limited liability company (the “Investor”).

 

RECITALS

 

A. WHEREAS, the Company may issue and sell to the Investor, and the Investor shall purchase from the Company, up to $7,500,000 of Convertible Promissory Notes (the “Notes”), convertible into shares of Common Stock; and

 

B. WHEREAS, pursuant to the terms of, and in consideration for the Investor entering into, that certain Note Purchase Agreement, dated on or about the Execution Date, by and between the Company and the Investor (the “Purchase Agreement”), and to induce the Investor to execute and deliver the Purchase Agreement, the Company has agreed to provide the Investor with certain registration rights with respect to the Registrable Securities (as defined herein) as set forth herein.

AGREEMENT

…

NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES FILED PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

Principal Amount: $1,670,000.00

Issue Date: June 9, 2026

 

CONVERTIBLE PROMISSORY NOTE

…

FATE THERAPEUTICS, INC.

THIRD AMENDED AND RESTATED 2022 STOCK OPTION AND INCENTIVE PLAN

SECTION 1.

GENERAL PURPOSE OF THE PLAN; DEFINITIONS

The name of the plan is the Fate Therapeutics, Inc. Third Amended and Restated 2022 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Fate Therapeutics, Inc. (the “Company”) and its Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby motivating their efforts on the Company’s behalf and strengthening their desire to remain with the Company.

The following terms shall be defined as set forth below:

“Act” means the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder.

…

ex101toform61526bowen2nd

US1 156220949 2 June 12, 2026 Personal & Confidential Adam K. Bowen 267 Glenwood Ave. SE Atlanta, GA 30312 Dear Adam, We are pleased to extend this offer of continued employment with Vestis in the position of Interim Chief Financial Officer of Vestis, effective June 12, 2026. While you remain in this position, you will be a member of our Executive Leadership Team and report directly to the Chief Executive Officer of Vestis Corporation. A Vestis Offer Summary specifying certain details associated with this offer of continued employment is attached to this offer letter (“Second Amended Vestis Offer Summary”). An amended and restated Agreement Relating to Employment and Post-Employment Competition (“Second Amended Employment Agreement”) is enclosed with this offer letter. This offer of continued employment in the position of Interim Chief Financial Officer of Vestis Corporation is contingent upon your execution of the Second Amended Employment Agreement. You are required at all times to comply with Vestis’ policies, including the Business Conduct Policy. Durin

…